Sera Prognostics, Inc.
SERAHealthcareNASDAQMedical Devices
Scan Results
Daily timeframeSera Prognostics, Inc., a women's health company, discovers, develops, and commercializes blood-based biomarker tests, and predictive analytic products and services in the United States. The company carries a $88.9M market cap, placing it firmly in the micro-cap category. The company develops the PreTRM test, a non-invasive blood test given to a pregnant woman, carrying a single fetus, during weeks 18 through 20 of gestation.
Market Cap
$88.9M
Beta
0.97
P/E (TTM)
—
P/E (Fwd)
-3.94
EPS (TTM)
$-0.64
EPS (Fwd)
$-0.58
ROE
-39.6%
ROA
-21.6%
Cash
$47.4M
Total Debt
$2.5M
Free CF
-$18.9M
52W Change
-21.2%
Annual Financials
Cash vs Debt
Where SERA stands vs its 150-day and 200-day moving averages
As of the July 7, 2026 close, SERA finished 14.34% below its 150-day moving average ($2.44) and 20.23% below its 200-day moving average ($2.62). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is SERA overbought or oversold?
At the July 7, 2026 close, SERA's RSI(14) was 65.3, in neutral territory (between 30 and 70). The MACD histogram was positive, so short-term momentum leaned bullish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
The balance sheet looks solid with $47.4M in cash comfortably exceeding the $2.5M debt load. A net cash position generally provides financial flexibility during uncertain economic periods. Free cash flow is running at -$18.9M, which bears watching. Negative free cash flow can be acceptable during heavy investment periods but needs to improve over time. ROE of -39.6% points to negative capital efficiency, indicating how much profit the company produces per dollar of shareholder equity. Revenue has been uneven over recent years, ranging from $268K to $81K.
With cash comfortably exceeding debt, SERA has financial flexibility that may help navigate uncertain periods. The company is burning cash at the operating level, which is not unusual for growth-phase companies but adds risk if it persists. These risk factors are not exhaustive — macroeconomic shifts, regulatory changes, and competitive dynamics can all influence Sera Prognostics, Inc.'s trajectory.